In addition to the evaluation in this paper, some teams independently validated their predictions (see Supporting Information Section 3. Pharm.ai compared their top 100 predictions for Nsp5 against public data published after the competition deadline and obtained a hit rate of 17% on a highly diverse set of scaffolds. An interaction-based drug discovery screen explains known SARS-CoV-2 inhibitors and predicts new compound scaffolds. The sarstrooper team experimentally tested top-ranked compounds they had submitted and found 7 inhibitors with IC 50 < 10 µM (Mukherjee et al., in preparation).